New drugs for peptic ulcer Advances in treatment depend not only on new drugs: new methods of measurement are also necessary. Doll's series of controlled clinical trials at the Central Middlesex Hospital depended on measurement of the area of a gastric ulcer in profile on barium meal before and after four weeks' treatment. These trials showed the significant advantages of bed rest, stopping smoking, and taking carbenoxolone for healing gastric ulcer. Healing of a duodenal ulcer could never be satisfactorily assessed radiologically; but fibreoptic duodenoscopy soon permitted double-blind, or preferably treble-blind, trials, which showed significant benefit from carbenoxolone, cimetidine, and bismuth in patients with duodenal (and gastric) ulcers.
New drugs for peptic ulcer are mostly the second generation of old types of drugs. Conventional anticholinergic drugs were always limited by their side effects; new ones are being developed. Anisotropine methylbromide, 80 mg at night, with antacids by day healed 11, 13, and 14 of 16 duodenal ulcers at two, four, and six weeks compared with six, eight, and 11 of 14 that healed in the placebo group.' Pirenzepine is the first selective anticholinergic, a tricyclic and pure antimuscarinic drug without appreciable H2-receptor-blocking activity.2 3 Unlike tricyclic antidepressants, pirenzepine is strongly hydrophilic with poor penetration into the brain; central nervous effects are unlikely. In conventional dosage side effects on the pupil, bladder, bowel, and heart have been minimal, suggesting that pirenzepine may have selective antimuscarinic properties. Subcellular studies, suggest that there are different subclasses of muscarinic receptors. Organs differ in the density of these subclasses and thus in their capacity to bind pirenzepine-which has low-affinity binding in smooth muscle and the heart and higher affinity in exocrine glands. 4 In clinical trials doses of 50 or 75 mg a day produced no significant improvement in the healing of gastric or duodenal ulcers, but 100 or 150 mg daily for four to six weeks was significantly more effective than placebo, and little less so than cimetidine.2 3 Pirenzepine has also been used in an attempt to prevent stress erosions as well as the dyspepsia associated with anti-inflammatory drugs. Further trials are needed from other centres. Pirenzepine and cimetidine together have additive inhibitory effects and the combination has been used to combat gross hypersecretion, as in the Zollinger-Ellison syndrome. 5 Glaxo's new H2-receptor antagonist, ranitidine, does not contain the imidazole nucleus previously thought essential for H2-receptor blockade,6 and is a more potent acid inhibitor than cimetidine,7-9 the plasma concentrations that reduce acid secretion by half being about 0-285 ,mol/l for ranitidine and 2 ,umol/l for cimetidine.'0 Ranitidine need be given only twice a day: with 100 mg twice daily 23 Trithiozine is an alkoxythiobenzamide said to have antisecretory and tranquillising properties without anticholinergic, antihistaminic, or ganglion-blocking effects. With the most common dose, 400 mg, the morning basal acid output is reduced by only 35-60%, and stimulated secretion by appreciably less, so that if trithiozine does increase the rate of healing of ulcers this could not plausibly be attributed to these moderate reductions in acid secretion. In Italy at least 11 controlled trials have shown increased healing of duodenal ulcer by trithiozine compared with placebo and in one trial trithiozine 1200 mg a day healed 17 of 23 ulcers in four weeks, a similar proportion to the 20 out of 25 in the group given cimetidine (1000 mg a day).17 We need more and larger trials. Proglumide, a derivative of isoglutamic acid, is said both to reduce gastric secretion and to improve mucosal resistance. In small trials recently proglumide, 1200 mg a day, healed significantly more gastric, but not duodenal, ulcers than did magnesium trisilicate in a dose of 1320 mg a day.'8 Pifarnine, another new Italian antisecretory drug, a piperazine derivative, healed nine of 14 duodenal ulcers in six weeks compared with the three out of 16 that healed in the placebo group. '9 Prostaglandin E2 is a normal constituent of human gastric mucosa and gastric secretions, and is present in lower-thannormal concentrations in patients with peptic ulcer. Experimentally, prostaglandin E inhibits gastric secretion, increases mucus, and prevents peptic ulceration. Prostaglandin E deficiency might therefore be a factor in human peptic ulcer. Synthetic analogues of prostaglandin E have been found beneficial in increasing the rate of healing of duodenal ulcer in Poland,20 and in a small trial in Singapore the synthetic methyl-E2 prostaglandin analogue increased the healing of gastric ulcer.2' Prostaglandins could act through a protective effect on mucosal cells as well as by inhibiting acid secretion.
The tricyclic antidepressant trimipramine has been found effective in Norway in both duodenal22 and gastric ulcer,23 and in combination with antacids was almost as effective as cimetidine.24 If these beneficial effects are confirmed in further trials we shall need to establish whether they are due to the drug's relatively weak antisecretory action, to a sedative effect, or even to an effect on H2-receptors in the brain. 25 Another tricyclic, butriptyline, however, taken at night with antacids by day, failed to increase the rate of healing of duodenal or gastric ulcers when compared with antacids alone. 26 The results of using pepsin antagonists have been uniformly disappointing. Amylopectin showed no significant benefit in patients with duodenal ulcer,27 28 and sucralfate showed none in those with gastric ulcer.29 Even pepstatin, the most potent in-vitro and in-vivo pepsin antagonist, was ineffective in a formal controlled trial in healing duodenal ulcer30 and in preventing recurrent bleeding in patients admitted with haematemesis and melaena. 31 Doctors are often sceptical of the suggestion that they themselves-or what they do-are a powerful form of treatment, independent ofthe pharmacological activity ofthe drugs they prescribe. We now have evidence for the first time that a placebo treatment for duodenal ulcer, intramuscular injections of saline, has significantly reduced the number of days of pain compared with no treatment at all.32 
Health services in higher education
All the universities in Britain and 18 of the polytechnics have established health services; but their nature depends both on the academic authorities and on local attitudes, especially among general practitioners and family practitioner committees. As a result of this diversity of opinion four main patterns have emerged, though no university or its health service is identical with any other. Firstly, the service may be fully comprehensive, with an open or restricted National Health Service list that includes students, staff, and families; an "occupational" and "industrial" health service; and visiting consultants, an inpatient unit, dental department, research, and training. Services of this kind are financed by the university, which receives the doctors' and dentists' earnings from the National Health Service and other sources. Some universities operate an insurance scheme for students and staff to partially cover those aspects of the service that are outside the National Health Service. A restricted list produces less money for the university.
A second pattern is based on an NHS general practitioner service housed in university property and attracting-payment for ancillary staff. This type of service cares for staff and students and provides most of the facilities mentioned above, but is less costly to the university funds. As the doctors are independent contractors they are less subject to university control.
Thirdly, some universities retain the services of local general practitioners on a part-time basis. The university provides accommodation or retainer fees or both for the doctors, who
